Overview
Evidence-based recommendations on tests in secondary care to identify people at high risk of ovarian cancer. The tests are the IOTA ADNEX model, Overa (MIA2G), RMI I (at thresholds other than 250), ROMA and IOTA Simple Rules.
Last reviewed: 15 November 2027
Diagnostics guidance 31 has been migrated to HealthTech guidance 453.
Next review: This guidance will be reviewed if there is new evidence that is likely to affect the recommendations.